Pharmaceutical Forum Concluded Successfully

ECThe final report of the Pharmaceutical Forum has been presented in Brussels setting out principles and recommendations on three key challenges in the pharmaceutical landscape. Firstly, how to improve information on diseases and treatments, secondly, how to compare medicines and identify the most effective ones and thirdly how to balance access and reward for innovation within limited healthcare budgets. The Pharmaceutical Forum was co-chaired by Günter Verheugen, Vice-President of the European Commission, and Commissioner Androulla Vassiliou. This meeting marks the end of a 3-year mandate. The Forum brought together Member States and stakeholders, including patient organisations, health professionals, industry and insurers. The final report comprises a set of principles and recommendations to increase cooperation in three key areas.

Vice President Verheugen, responsible for enterprise and industry policy said: "The Forum's recommendations can lead to important savings and permit a better reward for pharmaceutical innovation. I call upon industry and national authorities to help implementing these recommendations to the benefit of the patients and health care budget."

Commissioner Vassiliou, responsible for health policy, said: "Patients deserve prompt and equal access to the best medicinal products available, and EU cooperation on the relative effectiveness of drugs will help achieve that goal. I also welcome the concrete recommendations on information to patients on diseases and treatments as a major contribution to EU public health promotion policy."

Information to patients on diseases and treatments

The Forum has adopted recommendations to enhance access to and quality of information, such as:

  • Enhance quality of information: Core quality principles for the development of information to patients will enhance the quality of information by providing a clear and defined framework and also identify poor quality information. The Forum invites all health actors to refer to the agreed principles. The ban on advertising of prescription medicines should continue.
  • Increase accessibility: More information to citizens in effective communication formats should be provided (electronic and non-electronic means), taking account of local traditions, healthcare systems and languages.
  • Generation of information by making the best use of all actors: The Forum recommends Member States, the Commission and health actors to consider new collaborations in the field of information to patients. Such collaborations should respect the minimum ethical requirements: transparency, disclosure of financial and other support as well as definition of responsibilities.

Relative effectiveness

Member States, payers and patients face the common challenge of containing health care budgets, including pharmaceutical costs, while promoting and sustaining innovation properly. They therefore need to recognize the value of identifying the most effective medicines. The group reached agreement on:

  • Working definitions and good practice principles for Relative Effectiveness Assessment. These could serve as a basis for voluntary collaboration at EU level. A checklist to use these principles could provide a basis for self assessment at national level.
  • A stocktaking exercise on the existing methods.
  • A common analysis of existing technical and legal barriers to the development of relevant data.

Pricing and reimbursement

Final pricing and reimbursement decisions are usually required before patients can access new health solutions and innovative companies can obtain reward for their research. Although pricing and reimbursement decisions are made by individual Member States, they share the concern on balancing access and reward with limited resources. Concrete recommendations promote:

  • Optimal use of resources: A toolbox of knowledge should help to use limited resources optimally. The Group also discussed specific mechanisms like risk-sharing/conditional pricing and tendering and adopted Guiding Principles to help national authorities finding a balance between expenditure, access and innovation.
  • Access to medicines: The work focused on specific access problems related to small markets and to orphan medicines.
  • Reward of innovation: The expected value of innovation and potential reward mechanisms for innovative medicines have been analyzed in order to better match public health needs and long-term investments in R&D.

Follow up

Member States and stakeholders are invited to implement the recommendations of the Forum. The Commission will provide support to the strengthening of the cooperation tools. All background documents related to the work of the Pharmaceutical Forum are available at: http://ec.europa.eu/pharmaforum

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...